Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire,...
Transcript of Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire,...
![Page 1: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/1.jpg)
Outsourcing Clinical Trial
During a Merger
Dr. Leire,
CEO DanDrit Biotech A/S
Outsourcing Clinical Trials Conference. May 2014.
“"When it comes to mergers, hope
triumphs over experience."
Irwin Stelzer (1932–), US economist
![Page 2: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/2.jpg)
DanDrit Biotech: Developing the World’s First Colorectal Cancer Vaccine
Second generation dendritic cell cancer vaccine
Promising Phase II data colorectal and lung
cancers
Ongoing multicenter double-blind trial in
advanced colorectal cancer patients
![Page 3: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/3.jpg)
Merger of Biotech and Pharma
Do not address issues with mega merger between Pharmas
Even if there are different points of views
Positive returns to shareholders
McKinsey & Co: February 2014 by Myoung Cha and Theresa Lorriman
Fierce Pharma: Thumbs up or down on megamergers? Depends on your point of view
![Page 4: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/4.jpg)
Disruption Sap the life out of research
Focus and energy go into logistical decisions and away from science
Layoff worries
"Things that don't happen, drugs that don't get discovered--they make no sound at all," *
* Derek Lowe, In the pipeline
![Page 5: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/5.jpg)
Industry Ecology
BiotechCROsBig
Pharma
Authorities
From
“Research & Dev.”to
“Search & Dev.”
Concentrating
Increasing role
Increasing regulatory
hurdles
![Page 6: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/6.jpg)
2013 was a good year for M&A 169 deals
valued at $76 billion
compared to 2012
15% jump in number of deals
33% increase in dollars spent
Big
Pharma
*Reference: EvaluatePharma
![Page 7: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/7.jpg)
Big
Pharma
![Page 8: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/8.jpg)
Top 10 Deals 2013 1 Amgen / Onyx
2 Valeant / Bausch Lomb
3 Perrigo / Elan
4 Actavis / Warner Chilcott
5 AstraZeneca / BM's share of diabetes partnership
6 Shire / ViroPharma
7 Bayer / Algeta
8 Salix / Santarus
9 Mylan / Agila Specialties
10 AstraZeneca / Pearl Therapeutics
Big
Pharma
![Page 9: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/9.jpg)
Outsourcing innovation (buying
individual licenses or entering into
partnerships)
41%
Buying whole companies is the best
approach, especially in the biotech area
39%
In-house R&D is the most efficient
source of future innovations
20%
Reference: Pharmalot, And the weather report calls for a cloudy future, posted July 7, 2008
Rebuilding Pharma Pipeline
Big
Pharma
![Page 10: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/10.jpg)
Reference: Thomson Pharma; E. Saltzman, Defined Health 2011
Pharma Partnerships
Big
Pharma
![Page 11: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/11.jpg)
Valuation
$34 $99$162
$249
$440
$822
$1050 MarketValuationof a $350M(Peak Sales)ProductDevelopment
Risk
91%
77%
67%
56%32%
10%0%
Pro
ba
bil
ity o
f
Develo
pm
en
t F
ail
ure
Late Pre-Clinical Phase I Phase IIA Phase IIB Phase III NDA Filing Market
Risk / Value in Development
5/28/201411
Big
Pharma
![Page 12: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/12.jpg)
“A proliferating cancer within the
cancer trial process” Well-meaning bureaucratic functionaries have introduced
countless new regulations
Most often without field testing
Or consultation with clinical investigators
FDA final guidance on Risk Based Monitoring (RBM)
Authorities
![Page 13: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/13.jpg)
“A proliferating cancer within the
cancer trial process” Burdensome auditing and documentation requirements from
Authorities mean that it is usually easier to outsource data
management tasks to CROs
… which themselves introduce new hurdles for investigators
CROs
![Page 14: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/14.jpg)
Increasing Costs Cost per patient on a phase IIIA oncology trial
From an average of $3,000 to $5,000 in the early 1990s
To a range of $75,000 to $125,000 in 2013
In just 3 years: from 2008 to 2011
Per-patient clinical trial costs increased by 70%
Reference: Cutting Edge Information. Clinical operations: Benchmarking per-patient trial costs,
staffing and adaptive design.
Authorities
![Page 15: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/15.jpg)
Azactidine 1983 Azactidine 2012
Increasing Complexity
The entire protocol had
fewer than 10 pages
An IRB approved the
protocol within 1 week of
filing
Patients were enrolled and
treated the following week
The S1117 Intergroup study for myelodysplastic syndromes*
+2 years of preactivation
involved US and Canadian national cancer institutes, various cooperative groups, the National Cancer Institute's Cancer Therapy Evaluation Program
244 study locations: more study locations than the planned accrual of 240 patients
* ClinicalTrials.gov identifier: NCT01522976
Authorities
![Page 16: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/16.jpg)
Did this growth in cost and
complexity has convincingly made
the clinical trial process safer for
patients?
![Page 17: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/17.jpg)
This growth in cost and complexity
made clinical trial process more
dangerous for biotech
Longer trial:
More exposure to a change in major partner CRO
More chance to have a merger occurring while conducting a
clinical trial
Biotech
![Page 18: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/18.jpg)
Clinical Trials: 2/3 involve CROs
| CROs
![Page 19: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/19.jpg)
Global Nature of Clinical TrialsDatabases of experienced
investigators worldwide
Coordination
Knowledge of the SOC and
regulatory affairs in the country
the trials are being conducted
CROs
![Page 20: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/20.jpg)
Less Early Stage Developments Big Pharma concentrates on late-stage candidates
Emerging biotech narrows their pipeline under pressure of
investors
CROs
![Page 21: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/21.jpg)
Constantly Shifting Panorama
CRO Mergers Consolidation rather than megamergers
CROs
![Page 22: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/22.jpg)
Pharma Mega-merger Rumors Do
Not Benefit CROs* 3 to 7% drop in CRO’s share prices
Icon - 7.4%
Parexel - 6.9%
Quintile - 4%
Covance - 4%
* Jefferies, April 2014
CROs
![Page 23: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/23.jpg)
CROs and Biotechs:
Can We Get the Attention We Need?
Emergence of Virtual Biotech companies
Biotech: we are not Pharma
How to ensure our trial is valued by the CRO
CROs
![Page 24: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/24.jpg)
Strategic Partnerships Between large pharma companies and CROs
Biotech lack the volume of business to make such partnerships worthwhile
Maintain arm’s-length relationships with CROs
CROs
![Page 25: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/25.jpg)
Pharma Biotech
Different Type of Client!
Global
Expertise in place
Large in-house staff
Large pipeline
Slow decision process
Standard internal procedures
Rigidities
Less likely to accept third party role
Quality-driven
National
Lack expertise
Limited in-house staff
Focused pipeline
Fast decision process
Lack internal procedures
More flexible
More open to objective third party
Cost-driven
Biotech
![Page 26: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/26.jpg)
Different Types of Service
One-stop-shop
All-purpose partners or niche specialists
Complex TA such as oncology
Biotech
![Page 27: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/27.jpg)
Time versus RiskBiotechs’ goal: quickly capitalize drug candidates
Traditional model does not align incentives
i.e. the longer a trial takes to complete, the more a CRO is
paid
Your trial will be delayed
Seemingly smoothly running studies can have
hidden quality issues found long after end of trial
Caution: CROs will continue to consolidate
Biotech
![Page 28: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/28.jpg)
Service Agreement with CRODetailed
For some CROs, much of the profit comes from
change orders
Timing of payments
Contract directly with vendors, investigators and
sites
Include remedies
Protect your IP rights
DEFINE A WAY OUT
Biotech
![Page 29: Outsourcing Clinical Trial During a Merger · Outsourcing Clinical Trial During a Merger Dr. Leire, ... 1 Amgen / Onyx ... More chance to have a merger occurring while conducting](https://reader035.fdocuments.in/reader035/viewer/2022062504/5ae817727f8b9a08778f38e1/html5/thumbnails/29.jpg)
Increased Productivity
BiotechCROsBig
Pharma
Authorities
From
“Research & Dev.”to
“Search & Dev.”
Concentrating
Increasing role
Increasing regulatory and
reimbursement hurdles